Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.
Actively Recruiting
Researchers are assessing the long-term safety and tolerability of the Port Delivery System with ranibizumab PDS in people with neovascular age-related macular degeneration nAMD who have completed previous related studies or certain visits within those studies. The trial includes two sub-studies to evaluate specific aspects one tests the effectiveness of transscleral photocoagulation to reduce vitreous hemorrhages after PDS implantation, and the other assesses the safety of re-implantation with an updated PDS device. Participants receive the PDS implant with ranibizumab at a concentration of 100 mgmL, administered through refill-exchange procedures at set intervals varying by previous study involvement, typically every 24 weeks with some switching to every 12 weeks later in the trial. The sub-studies involve additional treatments such as laser therapy or re-implantation and follow-up for up to 72 weeks. Treatment schedules and monitoring differ depending on enrollment cohorts and prior participation. Throughout the study, participants undergo regular assessments including eye exams, imaging, and monitoring for adverse events related to the PDS implant and ranibizumab treatment. The study tracks vision changes, ocular health, device safety, and any complications over periods up to 240 weeks or longer if regulatory approval is pending. Participants adherence to visit schedules and safety measures are closely observed as part of the trials long-term evaluation.
Actively Recruiting
Researchers are evaluating the SING IMT prosthesis in patients aged 55 and older who have pseudophakic eyes eyes with implanted intraocular lenses and suffer from late-stage Age-Related Macular Degeneration AMD with moderate to profound bilateral central vision impairment. This international, randomized, multicenter study aims to expand the devices approved use and assess its safety and effectiveness in this specific patient group. The findings will support regulatory decisions, help clinical care, and may lead to label expansion for the device. The study involves two treatment approaches one where the SING IMT device replaces the existing intraocular lens IOL after removal Lens Exchange group, and another where the device is implanted in front of the existing IOL without removal Add-On group. Both procedures place the device in the sulcus area of the eye. Participants will be randomly assigned to one of these two groups. The trial includes multiple follow-up periods to assess outcomes after implantation. Participants will undergo vision tests and eye examinations at the start and then at 1, 3, and 6 months after the procedure. Key assessments include measuring the percentage of endothelial cell density ECD loss, visual acuity, and recording any surgical complications or adverse events. Patient-reported outcomes and the size of the incision needed for implantation will also be tracked. Participants are expected to engage in a postoperative training program for using the implant. The total study duration for each participant covers these assessments and monitoring visits.
Actively Recruiting
Researchers are evaluating the drug ADX-038 in participants aged 60 years and older who have geographic atrophy GA secondary to age-related macular degeneration AMD. This Phase 2, randomized, masked, placebo-controlled study aims to compare the effects of ADX-038 with a placebo on preserving the ellipsoid zone EZ layer in the eye over 12 months. The trial will also assess the safety, pharmacokinetics, and pharmacodynamics of ADX-038. Participants will receive either subcutaneous injections of ADX-038, a siRNA duplex oligonucleotide, or a saline placebo. The study uses a parallel design where participants are randomly assigned to one of these two groups. The treatment is administered over a 12-month period, during which the impact on eye structure and function will be closely monitored. Throughout the study, participants will attend clinic visits for assessments, including high-quality fundus imaging and other study-related procedures. They must complete meningococcal and pneumococcal vaccinations as required by the protocol. Researchers will monitor the preservation of the EZ layer as the primary outcome to evaluate treatment effect, alongside safety and drug behavior in the body. The total study duration extends until August 2030, with primary outcome results expected by February 2030.
Actively Recruiting
The trial investigates treatments for submacular haemorrhage SMH, a serious complication of wet age-related macular degeneration AMD that can cause severe vision loss. Researchers aim to compare the current standard treatment of anti-VEGF injections with a combination of anti-VEGF injections plus eye surgery to see if surgery improves vision outcomes. This is a phase 3 randomized controlled trial involving adults aged 50 and older with SMH due to wet AMD. Participants are randomly assigned to one of two groups one group receives standard anti-VEGF injections starting at baseline and continuing monthly for three doses, then every two months until 12 months. The other group receives the same anti-VEGF injection schedule combined with vitrectomy surgery, which involves removing the eyes vitreous gel, injecting a clot-busting drug TPA, and filling the eye with gas to help clear the blood clot. Surgery patients also follow specific head positioning after the procedure and have follow-up visits the day after and one week after surgery. Throughout the 12-month study, participants attend regular visits for injections and vision assessments, including tests of visual acuity and questionnaires about visual function and quality of life. Researchers measure vision improvement using Early Treatment of Diabetic Retinopathy Study ETDRS letter scores and other vision-related tests. Safety and vision are monitored with clinical exams at 6 and 12 months, and adherence to treatment schedules is tracked to evaluate the effectiveness of the treatments.